Nektar Therapeutics (NASDAQ:NKTR) stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin. Here’s what investors need to know. Nektar Therapeutics stock is showing notable weakness. What’s…
For U.S. mining investors, shifts in federal policy — particularly during the Donald Trump administration — have reshaped how capital evaluates large domestic projects. In an exclusive email interview with Benzinga, John Shively, CEO of Pebble Limited Partnership, said executive…
When investors think about insurance, they usually think about bonds or cash — not barrels, tons, or ounces. For Goldman Sachs, it’s commodities. As supply chains grow more concentrated, U.S.–China competition intensifies, and geopolitical conflicts increasingly spill into trade and…
China's dominance in mineral processing — not mining — is emerging as the defining fault line in the global race for critical resources such as copper. The U.S. imports roughly 60% of the copper it consumes — a reliance drawing…
Gilead Sciences, Inc. (NASDAQ:GILD) and Assembly Biosciences, Inc. (NASDAQ:ASMB) announced on Monday that Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent…
Carnival Corporation (NYSE:CCL) stock rose Monday after the cruise operator reported record fourth-quarter profit and cash flow. Following the results, Goldman Sachs analyst Lizzie Dove raised her price forecast to $34 from $31 and reiterated a Buy rating. Earnings Snapshot…
Immutep Limited (NASDAQ:IMMP) on Monday shared an update from the placebo-controlled, double-blind first-in-human Phase I study in healthy participants evaluating IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The single-ascending dose escalation portion of the trial completed the 2.5…
On Monday, the U.S. Food and Drug Administration (FDA) approved Abbott Laboratories’ (NYSE:ABT) Volt PFA System to treat patients battling atrial fibrillation (AFib). AFib is the most common type of irregular heart rhythm (arrhythmia) where the heart’s upper chambers (atria)…
CRISPR Therapeutics AG (NASDAQ:CRSP) on Monday provided updates on zugocaptagene geleucel (zugo-cel, formerly CTX112), its investigational allogeneic CAR T targeting CD19, in development for autoimmune disease and hematologic malignancies. Autoimmune Disease Zugo-cel, targeting CD19, is in an ongoing Phase 1 basket…
Fiserv, Inc. (NASDAQ:FISV) stock rose Monday after the payments technology provider announced two separate partnerships with Mastercard Inc. (NYSE:MA) and Visa Inc. (NYSE:V) aimed at advancing agentic commerce capabilities for merchants. Expanded Mastercard Partnership Fiserv said it has deepened its…